Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
Phase 2
Completed
- Conditions
- Graves' Ophthalmopathy
- Interventions
- Drug: RVT-1401
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 7
- Registration Number
- NCT03922321
- Locations
- π¨π¦
Toronto Retina Institute, North York, Ontario, Canada
π¨π¦CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont, Montreal, Quebec, Canada
π¨π¦UBC/VGH Eye Care Center, Vancouver, British Columbia, Canada
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Phase 2
Completed
- Conditions
- Myasthenia Gravis
- Interventions
- Drug: RVT-1401Drug: Placebo
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT03863080
- Locations
- πΊπΈ
IMC/Diagnostic and Medical Clinic, Mobile, Alabama, United States
πΊπΈCare Access Research, Pasadena, California, United States
π¨π¦Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
Β© Copyright 2025. All Rights Reserved by MedPath